ICML 2025 | Multi-targeted therapy with the ViPOR regimen plus polatuzumab in R/R DLBCL

Sure, so our ViPOR-Pola study I’ll be presenting on Friday as a poster presentation. It also builds upon our previous work using the ViPER regimen in diffuse large B-cell lymphoma. And the main takeaways from this is, first of all, it was a phase one study with a phase two expansion. In the safety portion of that study, we showed that the ViPER platform was able to be added to with this antibody drug conjugate, polatuzumab. We really did not see any additional significant notable toxicities compared to ViPER alone. And the ones we were worried about were things like neutropenia or neuropathy, which were very mild and manageable. It does appear to improve a little bit on the efficacy of ViPER. So over half of our patients with diffuse large B-cell lymphoma were up to 43 patients on that study, achieved a complete response to therapy. And based on some other published studies, such as the PolaRx, we actually did expand some treatment into patients with this non-GCB or ABC subtype of diffuse large B-cell lymphoma. And in some of those subsets, we’re now seeing 60 to upwards of 70, 75% achieve complete remission. And these two do appear durable. You know, overall, it was about 52% of patients were in durable remission at two years. Again, it’s enriched for these ABC. But in certain subtypes like non-germinal center or even the true ABC subtypes of diffuse large B-cell lymphoma, of patients remaining alive in a durable remission at the two year point. Again, some of these patients are now out past four or five years in remission, so we do think that it is cure, is more just, more evidence compared to the ViPER data that these targeted therapy combinations are curative in a subset of patients with relapsed/refractory diffuse large B-cell lymphoma.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.